Latest Allosteric regulation Stories
It is rare that an unpublished piece of research or theory remains significant after half a century. It is also a wonderful example of the boundless curiosity of the late Francis Crick. A previously unpublished work by Francis Crick and Jeffries Wyman from 1965 is now available, together with Jean-Pierre Changeux's recollections on the origins of the theory of Allostery and several important texts by various authors on the subject. These are part of a special issue of the Journal of Molecular...
Lee Rannals for redOrbit.com – Your Universe Online One new method may be able to lead to more effective medications, with fewer side effects, according to research published in the Journal of Neuroscience. Scientists from the University of Texas Medical Branch (UTMB) at Galveston and the University of Houston found a new way to influence the vital serotonin signaling system. The team linked malfunctions in serotonin signaling to a range of health issues, including everything from...
SAN DIEGO, July 13, 2012 /PRNewswire/ -- Receptos Inc. announced today the co-publication, in conjunction with the Stevens Lab at The Scripps Research Institute®, of key results relating to its expertise in the determination of high resolution G-protein coupled receptor (GPCR) crystal structures to enable rational drug discovery and design, including for allosteric modulators of GPCR receptors. The article, published in today's issue of Science and titled "Structural Basis for...
WELWYN GARDEN CITY, England and BOSTON, April 25, 2012 /PRNewswire/ -- Review published in Trends in Pharmacological Sciences Heptares Therapeutics, the leading GPCR drug discovery company, announces the recent publication of a major review of the state of the art for GPCR drug discovery and new insights that, for the first time, can be obtained from structural biology. The review has been published online in Trends in Pharmacological Sciences, a Cell...
XOMA Corporation (Nasdaq: XOMA) announced that its study of XMetA, the company's fully-human allosteric monoclonal antibody to the insulin receptor, is available online and will be published in the May issue of the American Diabetes Association's journal Diabetes. XMetA is the first antibody specific for the insulin receptor shown to correct hyperglycemia in a mouse model of diabetes. Results of a study conducted by XOMA and confirmed by investigators at the University of California, San...
SAN DIEGO, Feb. 16, 2012 /PRNewswire/ -- Receptos Inc. announced today the publication of key results relating to its expertise in S1P1 biology and structure-based drug discovery for high-value G-protein-coupled receptor (GPCR) targets in Science. The article, entitled "Crystal Structure of a Lipid G Protein-Coupled Receptor," was co-authored by Receptos in collaboration with scientific founders Hugh Rosen, M.D., Ph.D., and Raymond Stevens, Ph.D. Drs. Rosen and Stevens are...
SEATTLE, Jan. 17, 2012 /PRNewswire/ -- CompleGen, Inc. announced today that they have executed a non-exclusive services agreement regarding CompleGen's XenoGene(TM) technology. Boehringer Ingelheim's discovery team will apply the technology to explore targets that are not easily accessible by other discovery platforms. CompleGen's XenoGene(TM) technology uses the power of genetics to identify allosteric inhibitors that are selective for specific protein targets. "We are very...
SAN DIEGO, Jan. 10, 2012 /PRNewswire/ -- Receptos Inc. today announced the successful achievement of the technology transfer milestone under its license and technology transfer deal with Janssen Pharmaceuticals, Inc. (formerly Ortho-McNeil Janssen Pharmaceuticals, Inc.), for Receptos' breakthrough GPCR crystal structure determination technology. The relationship between Janssen Pharmaceuticals and Receptos, established in December 2010, enabled Janssen with the Receptos proprietary...
Precisely mapped allosteric binding site will facilitate design of drugs with minimal side effectsStructural biologists at Cold Spring Harbor Laboratory (CSHL) have obtained a precise molecular map of the binding site for an allosteric inhibitor in a subtype of the NMDA (N-methyl-D-aspartate) receptor, which is commonly expressed in brain cells.The newly discovered binding site -- a docking port within the receptor -- is important because it is a potential target for drugs that can modulate...
Multiple presentations at Society for Neuroscience 2010Allosteric modulation company Addex Pharmaceuticals (SIX:ADXN) announced today that data on a total of nine therapeutic programs will be presented during Society for Neuroscience 2010 (November 13-17, San Diego, USA), highlighting the strength of its allosteric modulation technology platform. The data being presented cover multiple receptor types and therapeutic areas, including Parkinson's disease, schizophrenia, anxiety, Alzheimer's...
